Thus, reduced expression of these 22 genes is significantly associated with improved outcome in p53 wild-type but not mutant NSCLCs, while heightened expression of these genes associates with worse outcome in p53 wild-type but not mutant NSCLC patients. This evidence concerns the gene TP53 and non-small cell lung carcinoma.